Analysts expect Protara Therapeutics to report a Q2 2026 net loss of $0.33 per share on zero revenue, while the stock currently trades at $4.06, well below the consensus analyst price target of $26.57.
Investors are primarily focused on the company's timeline for initiating the ADVANCED-3 registrational trial for its lead candidate, TARA-002, in bladder cancer patients. Recent 12-month clinical data showed a durable 55% complete response rate, reinforcing the pipeline's potential ahead of high-stakes registrational studies slated for the second half of 2026. Additionally, the market is tracking the company's cash burn and runway, previously guided to extend into 2028, to ensure adequate funding for these critical late-stage programs.